Common Virus May Cause a Type of Alzheimer’s
Researchers have discovered a link between a chronic gut infection caused by cytomegalovirus and the development of Alzheimer’s disease in some people.
Blood Test Can Predict How Long Vaccine Immunity Will Last
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.
CMS Releases Proposed 2026 Payment Policy Updates for MA and Part D Programs
The Centers for Medicare and Medicaid Services released the 2026 Advance Notice for the Medicare Advantage and the Medicare Part D Prescription Drug Programs that would update payment policies for these programs.
Triglyceride Drug Approved to Treat Adults with FCS
Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration to be used with diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome.
Coupling HA Molecules from Various Flu Strains Could Make Vaccines More Effective
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
HHS Announces 15 Additional Drugs for Price Negotiations
The Centers for Medicare and Medicaid Services (CMS) has announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations.
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration for use in individuals aged 10 through 25 years.
FDA Approves New Medication for Acute Pain
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.